# Quantum Sensing for Brain Applications (MEG/EEG) — QSMEC Integration

## Scope
Brain-focused extraction of the combined quantum document. Covers MEG/EEG use, OPM/SQUID/NV options, wearable feasibility, brain-specific use cases, and OC Healthcare integration.

## 1) Modalities for Brain
- SQUID MEG: 1–10 fT/√Hz, DC–1 kHz; clinical, shielded room, cryo.
- OPM MEG (SERF): 10–100 fT/√Hz, room temp, on‑scalp, wearable potential.
- NV-diamond: µm resolution; magnetic + electric + temperature sensing; research stage for macro-MEG.

## 2) Architectures
- On‑scalp OPM array (20–100+ sensors), field nulling coils, shielded room preferred.
- Classical MEMS EEG (8–64 ch) + OPM MEG sensor fusion for source localization.
- Timing: chip-scale atomic clock optional for multi-sensor sync.

## 3) Signal Targets
- EEG bands: Delta (0.5–4), Theta (4–8), Alpha (8–13), Beta (13–30), Gamma (30–100) Hz.
- MEG sensitivities: 10–1000 fT cortical fields, improved spatial fidelity vs. EEG-only.

## 4) Processing & Fusion
- Real-time filtering, artifact rejection (EMG/motion/power-line).
- Source localization: MNE/beamforming; investigate quantum-assisted optimizers (research).
- Multi-modal features: band power, connectivity, event-related fields.

## 5) Brain Use Cases
- Epilepsy focus mapping: 5–10 mm localization; pre-surgical planning.
- Functional mapping: motor/sensory/language with improved spatial/temporal resolution.
- Naturalistic neuro (OPM wearable): movement-tolerant paradigms, VR tasks.
- Stress/sleep cognition: Alpha/Beta dynamics, sleep stage studies with EEG+OPM.

## 6) Readiness & Constraints
- SQUID: clinical, costly, non‑portable.
- OPM: clinical trials, rapid progress; power/thermal management needed.
- NV: high resolution, not yet macro-scale brain sensing.

## 7) OC Healthcare Integration
- Stream EEG/MEG to cloud; HIPAA storage; FHIR Observations for brain metrics.
- AI models: CNN/Transformer for events, connectivity analysis; quantum ML exploratory.

## 8) Roadmap (Brain)
- Near-term: EEG + pilot OPM arrays for epilepsy and task-evoked studies.
- Mid-term: Wearable OPM for ambulatory research; clinical indications (epilepsy).
- Long-term: NV-enhanced focal sensing; consumer neuro-wearables (prosumer).

---

References: See canonical combined document for detailed citations. This file isolates brain-specific material for focused development.

See also:
- Heart counterpart: ../../Heart/QSMEC Integration/03_Quantum_Sensing_Heart_QSMEC.md

## 9) Wearable MEG in Motion: Naturalistic Paradigms

**Challenge:** Field-nulling strategies designed for static/shielded labs fail in motion. Head movement, muscle noise, and DC offset shifts degrade OPM sensitivity.

**Mitigation strategies:**
- **Reference sensors:** Nulling coils or co-located reference OPMs cancel environmental field variations (e.g., vehicle, motion artifact).
- **Gradiometer configuration:** First-order (axial) or second-order gradiometers suppress global fields; trade-off vs. focal sensitivity.
- **Adaptive cancellation:** Real-time Kalman/LMS filters track reference and subtract from signal sensors.
- **Helmet design:** Modular caps with flexible sensor placement; reduce weight/thermal load; enable longer sessions.
- **Paradigm design:** Brief event-related (e.g., button press, speech) vs. continuous; reduce demand on stabilization.

**Clinical examples:**
- Ambulatory epilepsy monitoring (home/field seizure events).
- VR-based motor/language tasks for post-stroke rehab.
- School/classroom neuro (pediatric ADHD, learning).

**Readiness (2025):** OPM vendors (Quspin, OPM-X, Magnes 3600) offering wearable helmets; early clinical pilots ongoing.

---

## 10) Pediatric MEG: Developmental & Tolerability

**Special considerations:**
- **Smaller head:** OPM arrays must be denser; 32–64 sensors on pediatric scalp feasible.
- **Helmet fit:** Quick-don modular designs; separate infant (<2 yrs), toddler (2–5 yrs), older child (6+) sizes.
- **Tolerability:** High motion artifact; patience required; brief (10–20 min) sessions; gamified paradigms (beeps, visual rewards).
- **Safety:** Standard MEG shielding/grounding; validate thermal safety on baby skin; no head restraints.

**Clinical applications:**
- Developmental language processing (age 6 months+).
- Childhood epilepsy (focal vs. generalized source localization).
- Autism spectrum: social brain networks, sensorimotor integration.
- ADHD: attention and impulse control mapping.

**IRB/regulatory nuances:**
- Pediatric assent/consent (age ≥7 typically); parental permission required.
- Risk category: minimal (no sedation, low magnetic fields); expedited review likely.
- Data safety: robust de-identification; limited secondary use without re-consent.

**Readiness (2025):** Growing pediatric MEG programs in leading US/EU centers (CHOP, Boston Children's, Karolinska); limited OPM helmet data (<500 children globally).

---

## 11) Regulatory Pathway for Brain MEG/EEG + Quantum Sensing

**Clinical indication strategy:**
1. **Initial focus (lower risk):**
   - Drug-refractory epilepsy pre-surgical mapping (existing clinical indication; MEG well-established).
   - Seizure focus localization; comparison to fMRI/intracranial EEG gold standard.

2. **Expansion (moderate risk):**
   - Post-stroke motor/language recovery monitoring (functional outcome predictor).
   - ADHD attention network mapping (research-to-clinical pathway).

**Regulatory classification:**
- **EEG add-on:** Class II (predicate 510(k); e.g., GE, Nihon Kohden systems); moderate controls.
- **OPM MEG head-worn system:** Likely Class II (predicate SQUID MEG systems like CTF, Elekta); performance equivalence needed.
- **Quantum-enhanced EEG:** Possible De Novo if sensitivity/specificity claim is novel (rare device pathway).

**IDE (Investigational Device Exemption) pathway:**
- **Phase 1:** Benchtop validation, safety (thermal, EMI, RF), small feasibility cohort (n=10–20 healthy).
- **Phase 2:** Target disease cohort (e.g., 30–50 drug-refractory epilepsy patients); compare source localization to accepted gold standard.
- **Phase 3:** Multi-center (3–5 sites), larger cohort (100–200), commercial system.

**Critical endpoints:**
- Sensitivity/specificity for seizure focus localization (vs. fMRI or intracranial EEG).
- Time-to-diagnosis, cost-effectiveness vs. current standard.
- Safety profile over 12–24 months.

**Estimated timeline:** Preclinical/IDE ramp (1–2 yrs) → Phase 2 trial (2–3 yrs) → Clearance/approval (1 yr) = **4–6 years total**.

**Key challenges:**
- Predicate device selection (existing SQUID MEG 510(k)s limited; novel software algorithms may require additional work).
- Multi-site standardization (vendor differences in sensors, helmets, processing).
- Reimbursement (CPT code negotiation; health economics studies needed).
